摘要
目的:探讨枸橼酸莫沙必利对帕金森综合征患者下消化道功能紊乱的治疗作用,阐明其作用机制。方法:选择伴有消化道功能紊乱的帕金森综合征患者29例,其中男性19例,女性10例,平均年龄68.7岁,每日给予枸橼酸莫沙必利15mg,分3次口服,连续3个月。测定患者结肠通过时间(CTT),行结直肠造影测定患者不同阶段直肠内压力和容量。结果:经枸橼酸莫沙必利治疗后,所有患者排便困难均好转。与治疗前比较,枸橼酸莫沙必利治疗后患者平均CTT缩短(P<0.05),尤其是左半部CTT缩短明显(P<0.01);与治疗前比较,枸橼酸莫沙必利治疗后,在直肠充盈的过程中,初发便意明显降低(P<0.05)。结论:枸橼酸莫沙必利作为一种新型5-HT4受体兴奋剂及5-HT3受体拮抗剂,对帕金森综合征患者具有促进结直肠蠕动及通便的作用。
Objective： To explore the therapeutic effect of mosapride citrate on lower gastrointestinal tract function disorder of the patients with Parkinson＇s syndrome, and to clarify its mechnism.Methods： A total of 29 patients with Parkinson＇s syndrome complicated with lower gastrointestinal tract function disorder （20 men,9 women; mean age, 68.7 years） were selected and treated with 15 mg of mosapride citrate 3 times a day,by oral for 3 months. The colonic transit time （CTT） of the patients was detected.and rectoanal videomanometry was used to measure the pressures and capacities in colon of the patients at different periods.Results： The defecation diffculties were improved after treated with mosapride citrate. Compared with before treatment, the mean CTT of the patients after treatment was shorten （P〈0.05）, expecially in the left colon （P〈0.01）. Compared with before treatment, mosapride augmented the amplitude in rectal contraction after treatment （P〈0.05） and lessened the volume of postdefecation residuals.Conclusion： As a kind of 5-HT4 receptor agonist and 5-HT3 receptor antagonistic agent, mosapride citrate can promote the lower gastrointestinal tract motility and ameliorate constipation in the Parkinson＇s syndrome patients.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2017年第1期125-129,共5页
Journal of Jilin University：Medicine Edition
基金
吉林省教育厅科研基金资助课题(2015-164
2013-162
2013-315)
